The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

To date, over 900 Duchenne patients have been treated with delandistrogene moxeparvovec. "The signal for ALF is exceptionally rare and has only emerged in the non-ambulatory patients," Sarepta's CEO ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Design A prospective longitudinal observational study across 17 neuromuscular centres in the UK of 360 boys aged 3–15 years with confirmed Duchenne muscular dystrophy who were treated with daily or ...

cNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA dDubowitz Neuromuscular Centre ...

"The ability of CAP-1002 to slow disease progression in Duchenne muscular dystrophy lies in the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of CDCs, which are mediated by ...

Background Duchenne muscular dystrophy is a x-linked, progressive, neuromuscular disease caused by mutations in DMD gene that abolish the production of dystrophin in muscle. 1 Delandistrogene ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD ... delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics), in patients aged 4 to 5 years, with the approval subsequently ...